Premium
THE EFFECTS OF PROLONGED BROMOCRIPTINE ADMINISTRATION ON PRL SECRETION GH AND GLYCAEMIC CONTROL IN STABLE INSULIN‐DEPENDENT DIABETES MELLITUS
Author(s) -
SCOBIE I.N.,
KESSON C.M.,
RATCLIFFE J.G.,
MACCUISH A.C.
Publication year - 1983
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1983.tb03200.x
Subject(s) - bromocriptine , endocrinology , medicine , prolactin , insulin , diabetes mellitus , secretion , chemistry , hormone
SUMMARY Plasma glucose, PRL and GH concentrations were measured at hourly intervals over a 24‐h period before and after oral bromocriptine administration in a dosage of 7±5 mg/day for 6 weeks in nine stable insulin‐dependent diabetic men. The pattern of PRL secretion was noted to be normal in stable diabetes (with a mean concentration of 205 mu/l ± 23 SEM) and was effectively suppressed by bromocriptine (to a mean concentration of 51 mu/l ± 2 SEM). This suppression of PRL secretion caused no major alteration in glycaemic control, mean plasma glucose for the group was 10±6 mmol/l ± 3± 4 SD before and 9±6 mmol/l ± 3·1 SD after bromocriptine administration. Bromocriptine produced no change in plasma glucose or GH profiles. It is concluded that PRL secretion is not a major influence on carbohydrate metabolism in stable diabetics.